Characteristics of long-term survival in advanced stage ovarian cancer: a nationwide cohort in the Netherlands

Objective: Despite optimal treatment with debulking surgery and chemotherapy, the majority of patients with advanced stage epithelial ovarian cancer (EOC) die within five years. Survival beyond eight years is rare and the mechanisms that lead to such favorable outcomes are incompletely understood. We aimed to identify characteristics associated with long-term survival (LTS) in a population-based cohort of patients with advanced stage EOC. Methods: Patients with advanced stage (FIGO IIB-IV) EOC diagnosed between 2008 and 2012 were identified from the Netherlands Cancer Registry. LTS was defined as survival for more than eight years after diagnosis, based on 20% survival within this cohort. Patient, tumor, and treatment characteristics were analyzed using multivariable logistic regression to find predictors for LTS. Results: We identified 2744 eligible patients of whom 571 were long-term survivors (survival longer than eight years). Younger age, lower tumor stage, low-grade histology, FIGO IV based on extra-abdominal lymph node compared to pleural metastasis, primary debulking surgery vs neo-adjuvant chemotherapy followed by interval debulking surgery, residual disease less than one cm or no macroscopic disease, and ascites less than 100 mL were associated with LTS. Furthermore, less than six chemotherapy cycles compared to six, and carboplatin plus paclitaxel combined with other chemotherapy agents compared to carboplatin plus paclitaxel, were associated with a lower odds of LTS. Conclusion: Characteristics of the tumor, patient and treatment play a substantial role in respect to the prognosis of advanced stage EOC, and can assist in the prediction of LTS.

Long-term survivor; Epithelial ovarian cancer; Prognostic factors; Cancer survivors

[1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA: A Cancer Journal for Clinicians. 2018; 68: 7–30.

[2] IKNL. Cijfersoverkanker. Available at:https://cijfersoverkanke r.nl(Accessed: 19 April 2020).

[3] Hennessy BT, Coleman RL, Markman M. Ovarian cancer. The Lancet. 2009; 374: 1371–1382.

[4] Timmermans M, Sonke GS, Van de Vijver KK, van der Aa MA, Kruitwagen RFPM. No improvement in long-term survival for epithelial ovarian cancer patients: a population-based study between 1989 and 2014 in the Netherlands. European Journal of Cancer. 2018; 88: 31–37.

[5] Karim-Kos HE, de Vries E, Soerjomataram I, Lemmens V, Siesling S, Coebergh JWW. Recent trends of cancer in Europe: a combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s. European Journal of Cancer. 2008; 44: 1345–1389.

[6] Baldwin LA, Huang B, Miller RW, Tucker T, Goodrich ST, Podzielinski I, et al. Ten-year relative survival for epithelial ovarian cancer. Obstetrics and Gynecology. 2012; 120: 612–618.

[7] Cress RD, Chen YS, Morris CR, Petersen M, Leiserowitz GS. Characteristics of Long-Term Survivors of Epithelial Ovarian Cancer. Obstetrics and Gynecology. 2015; 126: 491–497.

[8] Åkeson M, Jakobsen A, Zetterqvist B, Holmberg E, Brännström M, Horvath G. A Population-Based 5-Year Cohort Study Including all Cases of Epithelial Ovarian Cancer in Western Sweden: 10- Year Survival and Prognostic Factors. International Journal of Gynecologic Cancer. 2009; 19: 116–123.

[9] Dao F, Schlappe BA, Tseng J, Lester J, Nick AM, Lutgendorf SK, et al. Characteristics of 10-year survivors of high-grade serous ovarian carcinoma. Gynecologic Oncology. 2017; 141: 260–263.

[10] Hamilton CA, Miller A, Casablanca Y, Horowitz NS, Rungruang B, Krivak TC, et al. Clinicopathologic characteristics associated with long-term survival in advanced epithelial ovarian cancer: an NRG Oncology/Gynecologic Oncology Group ancillary data study. Gynecologic Oncology. 2018; 148: 275–280.

[11] Hoppenot C, Eckert MA, Tienda SM, Lengyel E. Who are the long-term survivors of high grade serous ovarian cancer? Gynecologic Oncology. 2018; 148: 204–212.

[12] Kaern J, Aghmesheh M, Nesland JM, Danielsen HE, Sandstad B, Friedlander M, et al. Prognostic factors in ovarian carcinoma stage III patients. can biomarkers improve the prediction of short- and long-term survivors? International Journal of Gynecological Cancer. 2005; 15: 1014–1022.

[13] Prat J, FIGO Committee on Gynecologic Oncology. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. International Journal of Gynaecology and Obstetrics. 2014; 124: 1–5.

[14] Fritz A, Percy C, Jack A, Shanmugaratnam K, Sobin LH, Parkin DM, et al. International classification of diseases for oncology. 3rd edn. World Health Organization: Geneva. 2000.

[15] Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. Journal of Clinical Epidemiology. 1994; 47: 1245–1251.

[16] Thrall MM, Goff BA, Symons RG, Flum DR, Gray HJ. Thirty-day mortality after primary cytoreductive surgery for advanced ovarian cancer in the elderly. Obstetrics and Gynecology. 2011; 118: 537–547.

[17] Heintz APM, Odicino F, Maisonneuve P, Quinn MA, Benedet JL, Creasman WT, et al. Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. International Journal of Gynaecology and Obstetrics. 2006; 95: S161–S192.

[18] Chi DS, Liao JB, Leon LF, Venkatraman ES, Hensley ML, Bhaskaran D, et al. Identification of prognostic factors in advanced epithelial ovarian carcinoma. Gynecologic Oncology. 2001; 82: 532–537.

[19] Deng K, Yang C, Tan Q, Song W, Lu M, Zhao W, et al. Sites of distant metastases and overall survival in ovarian cancer: a study of 1481 patients. Gynecologic Oncology. 2018; 150: 460–465.

[20] Timmermans M, Sonke GS, Van de Vijver KK, Ottevanger PB, Nijman HW, van der Aa MA, et al. Localization of distant metastases defines prognosis and treatment efficacy in patients with FIGO stage IV ovarian cancer. International Journal of Gynecological Cancer. 2019; 29: 392–397.

[21] Tingulstad S, Skjeldestad FE, Halvorsen TB, Hagen B. Survival and prognostic factors in patients with ovarian cancer. Obstetrics and Gynecology. 2003; 101: 885–891.

[22] Peres LC, Cushing-Haugen KL, Köbel M, Harris HR, Berchuck A, Rossing MA, et al. Invasive Epithelial Ovarian Cancer Survival by Histotype and Disease Stage. Journal of the National Cancer Institute. 2019; 111: 60–68.

[23] Hess V, A’Hern R, Nasiri N, King DM, Blake PR, Barton DPJ, et al. Mucinous Epithelial Ovarian Cancer: a Separate Entity Requiring Specific Treatment. Journal of Clinical Oncology. 2004; 22: 1040–1044.

[24] Pectasides D, Fountzilas G, Aravantinos G, Kalofonos C, Efstathiou H, Farmakis D, et al. Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience. Gynecologic Oncology. 2006; 102: 285–291.

[25] Jelovac D, Armstrong DK. Recent progress in the diagnosis and treatment of ovarian cancer. CA: A Cancer Journal for Clinicians. 2011; 61: 183–203.

[26] Cooper BC, Sood AK, Davis CS, Ritchie JM, Sorosky JI, Anderson B, et al. Preoperative CA 125 levels: an independent prognostic factor for epithelial ovarian cancer. Obstetrics and Gynecology. 2002; 100: 59–64.

[27] Bonnefoi H, A’Hern RP, Fisher C, Macfarlane V, Barton D, Blake P, et al. Natural history of stage IV epithelial ovarian cancer. Journal of Clinical Oncology. 1999; 17: 767–775.

[28] von Gruenigen VE, Frasure HE, Reidy AM, Gil KM. Clinical disease course during the last year in ovarian cancer. Gynecologic Oncology. 2003; 90: 619–624.

[29] Winter WE, Maxwell GL, Tian C, Sundborg MJ, Rose GS, Rose PG, et al. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology. 2008; 26: 83–89.

[30] Timmermans M, van der Hel O, Sonke GS, Van de Vijver KK, van der Aa MA, Kruitwagen RF. The prognostic value of residual disease after neoadjuvant chemotherapy in advanced ovarian cancer; a systematic review. Gynecologic Oncology. 2019; 153: 445–451.

[31] Wright AA, Bohlke K, Armstrong DK, Bookman MA, Cliby WA, Coleman RL, et al. Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology. 2016; 34: 3460–3473.

[32] Kehoe S, Hook J, Nankivell M, Jayson GC, Kitchener H, Lopes T, et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet. 2015; 386: 249–257.

[33] Morgan RJ, Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Behbakht K, Chen L, et al. Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network. 2016; 14: 1134–1163.

[34] Dizon DS, Weitzen S, Rojan A, Schwartz J, Miller J, Disilvestro P, et al. Two for good measure: six versus eight cycles of carboplatin and paclitaxel as adjuvant treatment for epithelial ovarian cancer. Gynecologic Oncology. 2006; 100: 417–421.

[35] Kim HS, Park NH, Chung HH, Kim JW, Song YS, Kang SB. Are three additional cycles of chemotherapy useful in patients with advanced-stage epithelial ovarian cancer after a complete response to six cycles of intravenous adjuvant paclitaxel and carboplatin? Japanese Journal of Clinical Oncology. 2008; 38: 445–450.